Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 33.94% is 47% below its 5-year average of 64.62%, around the middle of its 5-year range (-10.50%–72.22%).
21.98% below its 12-month average of 43.50%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 63.89%.
GROSS MARGIN
33.94%
GROSS MARGIN AVG TTM
43.50%
GROSS MARGIN AVG 3Y
54.63%
GROSS MARGIN AVG 5Y
64.62%
GROSS MARGIN AVG 10Y
59.82%
GROSS MARGIN AVG 15Y
52.47%
GROSS MARGIN AVG 20Y
49.69%
CURRENT VS TTM AVG
-21.98%
CURRENT VS 3Y AVG
-37.87%
CURRENT VS 5Y AVG
-47.48%
CURRENT VS 10Y AVG
-43.26%
CURRENT VS 15Y AVG
-35.32%
CURRENT VS 20Y AVG
-31.69%
SECTOR MEDIAN · HEALTHCARE
41.76%
median of 631 covered companies
CURRENT VS SECTOR MEDIAN
-18.73%
vs the sector median at left
Apyx Medical Corporation
Market Cap
$108.64M
Gross Margin
33.94%
TTM Avg
43.50%
3Y Avg
54.63%
5Y Avg
64.62%
Market Cap
$108.29M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
2.35%
Market Cap
$109.42M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$107.44M
Gross Margin
99.54%
TTM Avg
49.77%
3Y Avg
24.89%
5Y Avg
16.59%
Market Cap
$107.28M
Gross Margin
83.37%
TTM Avg
83.81%
3Y Avg
82.64%
5Y Avg
80.50%
Market Cap
$110.05M
Gross Margin
46.49%
TTM Avg
23.25%
3Y Avg
11.62%
5Y Avg
7.75%
Market Cap
$105.48M
Gross Margin
71.67%
TTM Avg
77.09%
3Y Avg
79.04%
5Y Avg
77.65%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Apyx Medical Corporation (APYX) | $108.64M | 33.94% | 43.50% | 54.63% | 64.62% |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP)vs › | $108.29M | 0.00% | 0.00% | 0.00% | 2.35% |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $109.42M | 0.00% | 0.00% | 0.00% | 0.00% |
| Immunic, Inc. (IMUX)vs › | $107.75M | 0.00% | 0.00% | 0.00% | 0.00% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $107.44M | 99.54% | 49.77% | 24.89% | 16.59% |
| Cumberland Pharmaceuticals Inc. (CPIX)vs › | $107.28M | 83.37% | 83.81% | 82.64% | 80.50% |
| Outlook Therapeutics, Inc. (OTLK)vs › | $110.05M | 46.49% | 23.25% | 11.62% | 7.75% |
| BGM Group Ltd. (BGM)vs › | $111.14M | 12.79% | 14.59% | 10.64% | 11.25% |
| Definitive Healthcare Corp. (DH)vs › | $105.48M | 71.67% | 77.09% | 79.04% | 77.65% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.30M | 99.91% | -67.10% | -31.47% | -20.98% |
Gross Margin
33.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 63.89% |
| 2026-03-31 | 37.41% |
| 2025-12-31 | -10.50% |
| 2025-09-30 | 64.43% |
| 2025-06-30 | 62.28% |
| 2025-03-31 | 60.07% |
| 2024-12-31 | 63.03% |
| 2024-09-30 | 60.54% |
| 2024-06-30 | 23.14% |
| 2024-03-31 | 58.07% |
| 2023-12-31 | 27.70% |
| 2023-09-30 | 66.62% |
| 2023-06-30 | 68.38% |
| 2023-03-31 | 62.37% |
| 2022-12-31 | 65.35% |
| 2022-09-30 | 63.17% |
| 2022-06-30 | 67.18% |
| 2022-03-31 | 65.79% |
| 2021-12-31 | 72.22% |
| 2021-09-30 | 68.09% |
| 2021-06-30 | 67.12% |
| 2021-03-31 | 67.84% |
| 2020-12-31 | 67.18% |
| 2020-09-30 | 67.95% |
| 2020-06-30 | 48.74% |
| 2020-03-31 | 59.72% |
| 2019-12-31 | 71.83% |
| 2019-09-30 | 66.23% |
| 2019-06-30 | 68.09% |
| 2019-03-31 | 63.88% |
| 2018-12-31 | 59.45% |
| 2018-09-30 | 68.65% |
| 2018-06-30 | 54.70% |
| 2018-03-31 | 50.32% |
| 2017-12-31 | 51.98% |
| 2017-09-30 | 49.15% |
| 2017-06-30 | 51.45% |
| 2017-03-31 | 50.38% |
| 2016-12-31 | 50.87% |
| 2016-09-30 | 50.30% |
| 2016-06-30 | 50.56% |
| 2016-03-31 | 42.74% |
| 2015-12-31 | 42.37% |
| 2015-09-30 | 41.28% |
| 2015-06-30 | 43.17% |
| 2015-03-31 | 43.64% |
| 2014-12-31 | 32.69% |
| 2014-09-30 | 28.27% |
| 2014-06-30 | 27.03% |
| 2014-03-31 | 42.52% |
| 2013-12-31 | 41.91% |
| 2013-09-30 | 38.82% |
| 2013-06-30 | 36.91% |
| 2013-03-31 | 37.76% |
| 2012-12-31 | 40.82% |
| 2012-09-30 | 43.38% |
| 2012-06-30 | 38.39% |
| 2012-03-31 | 41.53% |
| 2011-12-31 | 42.96% |
| 2011-09-30 | 41.66% |
| 2011-06-30 | 44.51% |
| 2011-03-31 | 39.54% |
| 2010-12-31 | 43.05% |
| 2010-09-30 | 41.59% |
| 2010-06-30 | 39.28% |
| 2010-03-31 | 40.81% |
| 2009-12-31 | 42.76% |
| 2009-09-30 | 43.32% |
| 2009-06-30 | 43.64% |
| 2009-03-31 | 46.00% |
| 2008-12-31 | 43.84% |
| 2008-09-30 | 44.32% |
| 2008-06-30 | 41.52% |
| 2008-03-31 | 38.73% |
| 2007-12-31 | 37.01% |
| 2007-09-30 | 41.77% |
| 2007-06-30 | 40.84% |
| 2007-03-31 | 37.03% |
| 2006-12-31 | 37.44% |
| 2006-09-30 | 41.16% |
| 2006-06-30 | 42.91% |
| 2006-03-31 | 38.36% |
| 2005-12-31 | 41.08% |
| 2005-09-30 | 41.97% |
| 2005-06-30 | 31.44% |
| 2005-03-31 | 34.80% |
| 2004-12-31 | 38.02% |
| 2004-09-30 | 40.41% |
| 2004-06-30 | 41.63% |
| 2004-03-31 | 38.79% |
| 2003-12-31 | 42.30% |
| 2003-09-30 | 41.87% |
| 2003-06-30 | 45.12% |
| 2003-03-31 | 42.59% |
| 2002-12-31 | 36.23% |
| 2002-09-30 | 51.38% |
